With its lead cancer drug, CX-3543, finishing up Phase I development, privately held Cylene Pharmaceuticals Inc. closed a $44 million Series C round to fund upcoming Phase II trials of the small molecule in multiple indications, starting with chronic lymphocytic leukemia. (BioWorld Today) Read More
